Clinical Report: FDA Approval of Semaglutide 7.2 mg (Wegovy HD) for Obesity

Overview

The FDA has approved semaglutide 7.2 mg (Wegovy HD) for adults with obesity, based on robust weight loss results from the phase 3 STEP UP trials. This once-weekly injectable demonstrated significant mean weight reductions and favorable safety consistent with prior semaglutide studies.

Background

Obesity is a major public health challenge associated with increased risk of type 2 diabetes, cardiovascular disease, and metabolic dysfunction. Semaglutide, a glucagon-like peptide-1 receptor agonist, has been previously approved in lower doses for weight management and related indications. The new 7.2 mg dose (Wegovy HD) aims to provide enhanced efficacy in reducing excess body weight and maintaining long-term weight loss. The FDA’s approval was expedited with a Commissioner’s National Priority Voucher, highlighting its importance in addressing obesity.

Data Highlights

Key Findings

• Semaglutide 7.2 mg once weekly led to a mean weight loss of 20.7% in adults with obesity over 72 weeks.
• In adults with obesity and type 2 diabetes, mean weight loss was 14.1% with semaglutide 7.2 mg.
• Nearly one-third (31.2%) of patients without diabetes achieved ≥25% weight loss; over one-fifth (21.3%) of patients with diabetes achieved ≥20% weight loss.
• The safety and tolerability profile was consistent with previous semaglutide weight management studies.
• Wegovy is available in multiple formulations and doses, including injectable (1.7 mg, 2.4 mg, 7.2 mg) and oral forms.
• FDA approval includes indications for cardiovascular risk reduction and treatment of metabolic dysfunction–associated steatohepatitis.

Clinical Implications

Semaglutide 7.2 mg offers a potent pharmacologic option for significant and sustained weight loss in adults with obesity, including those with type 2 diabetes. Its favorable safety profile supports its use alongside lifestyle interventions. Clinicians should consider this therapy as part of a comprehensive obesity management plan, especially for patients at high cardiometabolic risk.

Conclusion

The FDA approval of semaglutide 7.2 mg (Wegovy HD) marks an important advancement in obesity treatment, providing a highly effective once-weekly injectable option to achieve substantial weight loss and improve related health outcomes.

References

1. Novo Nordisk 2024 -- FDA Approves Semaglutide 7.2 mg (Wegovy HD) for Obesity